Certara, Inc. $CERT Stock Holdings Boosted by Roubaix Capital LLC

Roubaix Capital LLC raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 83.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 519,776 shares of the company’s stock after acquiring an additional 236,568 shares during the period. Certara makes up 3.0% of Roubaix Capital LLC’s investment portfolio, making the stock its 8th biggest holding. Roubaix Capital LLC owned 0.33% of Certara worth $6,352,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Wasatch Advisors LP increased its holdings in shares of Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after purchasing an additional 4,244,230 shares during the period. Marshall Wace LLP grew its position in Certara by 1,430.6% in the 2nd quarter. Marshall Wace LLP now owns 1,512,343 shares of the company’s stock valued at $17,694,000 after buying an additional 1,413,538 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after buying an additional 1,165,064 shares during the period. Fort Washington Investment Advisors Inc. OH purchased a new position in Certara during the 3rd quarter worth $11,899,000. Finally, Mackenzie Financial Corp raised its position in Certara by 47.7% during the 2nd quarter. Mackenzie Financial Corp now owns 2,648,549 shares of the company’s stock worth $30,988,000 after buying an additional 855,222 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Down 0.4%

Certara stock opened at $7.05 on Tuesday. Certara, Inc. has a fifty-two week low of $6.04 and a fifty-two week high of $15.38. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -705.00 and a beta of 1.47. The stock’s fifty day moving average is $8.32 and its two-hundred day moving average is $9.85. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the firm earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CERT shares. Rothschild & Co Redburn set a $10.00 target price on shares of Certara in a report on Friday, November 21st. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. Craig Hallum cut Certara from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a research report on Friday. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Finally, BMO Capital Markets began coverage on Certara in a research note on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.10.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.